Vibrio harveyi phage therapy is moving from theory toward practice. A 2026 study isolated a new lytic phage, vB_VhaM_HVS-1, from sea cucumber farming ponds. It attached to more than 85 percent of host bacteria within 5 minutes, released about 168 new phage particles per infected cell, cut bacterial attachment to host cells to nearly zero, and restored host cell viability from 78.17 to 88.54 percent after infection. The phage carries no antibiotic resistance or virulence genes and does not infect humans or farm animals. It is a precision tool, not a blanket antibiotic replacement. Why Vibrio harveyi is a problem that keeps growing Vibrio harveyi sits near the top of…